Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tissue Renewal without Stem Cells

Tissue Renewal without Stem Cells

After cellular or tissue damage, the resident stem cells present in the human body can locally repair and regenerate the damaged tissue or organ. However, even though some tissues do not have stem cells, they can repair and regenerate with the help of pre-existing cells. For example, beta cells of the pancreas and hepatocytes of the liver can divide to renew and regenerate the tissue. Here, both cell division and cell death are well regulated by homeostasis.
However, failure of such a system...

Insulin: Biosynthesis, Chemistry, and Preparation

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Adaptive islet biology and comprehensive incretin physiology: Emerging perspectives from Asia and Europe.

Journal of diabetes investigation·2026

Same author

Cardiovascular Efficacy of GLP-1 Receptor Agonists by Kidney Function: An Updated Meta-Analysis of Randomized Trials Including the SOUL Trial.

Diabetes, obesity & metabolism·2026

Same author

Response to Comment on Sakaki et al. Quantitative β-Cell Mass Imaging Redefines Disease Staging and Glycemic Control in Type 1 Diabetes.

Diabetes·2026

Same author

Activating Transcription Factor 6α Governs Stress-Adaptive Pancreatic β-Cell Mass Expansion by Coordinating Proliferation and Survival.

Diabetes·2026

Same author

ChREBP drives β-cell proliferation under metabolic stress but not in pregnancy-induced β-cell expansion.

Journal of diabetes investigation·2026

Same author

Estimated Glomerular Filtration Rate Change and Heart Failure Events With GLP-1 Receptor Agonists: A Meta-Analysis and Meta-Regression of Randomised Controlled Trials.

Diabetes, obesity & metabolism·2026

Search research articles

Related Experiment Video

Updated: Feb 21, 2026

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

Published on: July 16, 2016

Beta-cell replacement strategies for diabetes.

Timothy J Kieffer^1,2, Knut Woltjen^2,3, Kenji Osafune¹

¹Department of Cellular & Physiological Sciences, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, Canada.

Journal of Diabetes Investigation

|October 7, 2017

Summary

Researchers are exploring new ways to replace pancreatic islet beta cells for diabetes treatment. Strategies include cell transplantation, stem cell differentiation, and genetic engineering for personalized medicine.

Keywords:

Genetic engineering Islet transplantation Stem cell

More Related Videos

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Related Experiment Videos

Last Updated: Feb 21, 2026

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

Published on: July 16, 2016

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Area of Science:

Endocrinology and Metabolism
Regenerative Medicine
Bioengineering

Background:

Diabetes mellitus results from insufficient insulin production due to pancreatic islet beta-cell loss or dysfunction.
Current treatments focus on managing blood glucose, but beta-cell replacement offers a potential cure.

Purpose of the Study:

To review recent advancements in beta-cell replacement strategies for diabetes treatment.
To discuss the feasibility and challenges of various therapeutic approaches, including cell transplantation and regenerative medicine.

Main Methods:

Review of symposium discussions on beta-cell replacement therapies.
Exploration of islet transplantation, xenotransplantation (pig pancreas), and in vitro stem cell differentiation.
Investigation of immune-isolation techniques (macro-encapsulation, microfibers) and genetic engineering tools.

Main Results:

Human islet transplantation is effective but limited by cell supply.
Generating human islets from pigs presents scientific and ethical hurdles.
Human embryonic stem cells and induced pluripotent stem cells are promising sources for beta-cell replacement, with some already in clinical trials.

Conclusions:

Multiple promising avenues exist for beta-cell replacement therapy in diabetes.
Advancements in stem cell technology and genetic engineering are crucial for future treatments.
Further research is essential to develop safe, effective, and potentially personalized beta-cell replacement strategies.